<DOC>
	<DOC>NCT00153608</DOC>
	<brief_summary>In this trial HLA-A2+ patients with WT1 expressing carcinomas are vaccinated with a peptide from the leukemia associated antigen WT1 together with immunological adjuvants KLH as T-helper protein and GM-CSF</brief_summary>
	<brief_title>WT1 Peptid Vaccination in Carcinomas</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<criteria>Metastatic cancer, no standard treatment option Resected cancer with minimal residual disease, no standard treatment option WT1 expression HLAA2 Concurrent chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>